This study tests a new medicine called BMF-500 for adults with acute leukemia, a type of blood cancer. BMF-500 is a pill that targets a gene called FLT3, which is often abnormal in leukemia. The study is in its early phase, meaning it's the first time humans are trying this medicine. The study is looking for adults 18 and older who have acute myeloid leukemia (AML), which is a fast-growing cancer of the blood and bone marrow. Participants should have a certain gene mutation or similar conditions and must be physically fit (ECOG status 0-2). They also need good liver and kidney function.

• The study lasts for about 4 weeks, requiring continuation of certain antifungal medicines if needed.
• Participants must avoid certain medicines before and during the study.
• People with heart problems or very high white blood cell counts cannot join.

If you're eligible and interested, this study could be an opportunity to try a new treatment. However, there are risks, and it's important to discuss them with your doctor.